{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T13:42:29Z","timestamp":1753882949251,"version":"3.41.2"},"reference-count":24,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Genesis Pharma SA"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis Journal - Experimental, Translational and Clinical"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p> Natalizumab is a highly efficacious treatment for relapsing-remitting multiple sclerosis (RRMS). <\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p> To assess the real-world long-term safety of natalizumab in RRMS. <\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p> This multicenter, 5-year prospective observational study, included adults with RRMS newly initiated on natalizumab as per the approved product label in the routine care in Greece. Safety was evaluated by collecting serious adverse events (SAEs) following study enrollment. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> Between 19-Apr-2012 and 18-Dec-2014, 304 eligible patients (median age at natalizumab initiation: 38.0\u2009years; median disease duration: 6.2\u2009years) were enrolled by 20 hospital-based neurologists. Over a median treatment duration period of 58.7\u2009months, 50.7% of the patients discontinued natalizumab, mainly due to anti-JCV antibody detection (59.1%). The adverse event treatment discontinuation rate was 5.2%. The SAE incidence rate during the safety data collection period (median: 48.7\u2009months) was 4.6%. The most common SAEs were infections (1.0%), including 2 cases (0.7%) of progressive multifocal leukoencephalopathy (PML), and no other opportunistic infections. PML diagnoses occurred 6.2-6.7\u2009years after natalizumab initiation, and approximately 2\u2009years after first detection of anti-JCV antibody for both patients. The incidence rate of malignancies was 0.7%. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> In real-world settings in Greece, natalizumab displayed an acceptable safety profile, with no new safety signals emerging. <\/jats:p><\/jats:sec>","DOI":"10.1177\/20552173211035803","type":"journal-article","created":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T01:48:29Z","timestamp":1627609709000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Patient and treatment characteristics and safety outcomes of patients with relapsing-remitting multiple sclerosis treated with natalizumab in Greece: Results from the multicenter, 5-year prospective observational study \u2018TOPICS greece\u2019"],"prefix":"10.1177","volume":"7","author":[{"given":"Panagiotis","family":"Karanasios","sequence":"first","affiliation":[{"name":"Department of Neurology, \u201cSaint Andrew\u2019s\u201d General Hospital of Patras Agios Andreas, Patras, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios","family":"Karachalios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7421-9035","authenticated-orcid":false,"given":"Rania","family":"Gourgioti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonia","family":"Alexopoulou","sequence":"additional","affiliation":[{"name":"Genesis Pharma S.A, CNS Department, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasileios","family":"Mastorodemos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"TOPICS Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2021,7,29]]},"reference":[{"key":"bibr1-20552173211035803","unstructured":"Tysabri. Summary of product characteristics, www.ema.europa.eu\/en\/documents\/product-information\/tysabri-epar-product-information_en.pdf (2020, accessed 08 February 2021)."},{"key":"bibr2-20552173211035803","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.4.4.571"},{"key":"bibr3-20552173211035803","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMct071462"},{"key":"bibr4-20552173211035803","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2013.598"},{"key":"bibr5-20552173211035803","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044397"},{"key":"bibr6-20552173211035803","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044396"},{"key":"bibr7-20552173211035803","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1601358"},{"key":"bibr8-20552173211035803","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-020-00427-y"},{"key":"bibr9-20552173211035803","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1212\/WNL.94.15_supplement.2815","volume":"94","author":"Giovannoni G","year":"2020","journal-title":"Neurology"},{"key":"bibr10-20552173211035803","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107829"},{"key":"bibr11-20552173211035803","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.579438"},{"key":"bibr12-20552173211035803","doi-asserted-by":"publisher","DOI":"10.1177\/1352458511435105"},{"key":"bibr13-20552173211035803","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1136\/jnnp-2016-315106.113","volume":"87","author":"McGuigan C","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"bibr14-20552173211035803","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.101863"},{"key":"bibr15-20552173211035803","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2019-322326"},{"key":"bibr16-20552173211035803","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000541"},{"key":"bibr17-20552173211035803","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12204"},{"key":"bibr18-20552173211035803","unstructured":"European Medicines Agency, EMA confirms recommendations to minimise risk of brain infection PML with Tysabri. www.ema.europa.eu\/en\/documents\/referral\/tysabri-article-20-procedure-ema-confirms-recommendations-minimise-risk-brain-infection-pml-tysabri_en.pdf (2016, accessed March 2021)."},{"key":"bibr19-20552173211035803","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30282-X"},{"key":"bibr20-20552173211035803","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24286"},{"key":"bibr21-20552173211035803","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0174858"},{"key":"bibr22-20552173211035803","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0217303"},{"key":"bibr23-20552173211035803","doi-asserted-by":"publisher","DOI":"10.1177\/1352458513505353"},{"key":"bibr24-20552173211035803","doi-asserted-by":"crossref","unstructured":"Guger M, Enzinger C, Leutmezer F, et al. Austrian MS treatment registry (AMSTR). Long-term outcome and predictors of long-term disease activity in natalizumab-treated patients with multiple sclerosis: real life data from the Austrian MS treatment registry. J Neurol. Epub ahead of print 2021. DOI: 10.1007\/s00415-021-10559-w.","DOI":"10.1007\/s00415-021-10559-w"}],"container-title":["Multiple Sclerosis Journal - Experimental, Translational and Clinical"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20552173211035803","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20552173211035803","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20552173211035803","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T18:39:14Z","timestamp":1740767954000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20552173211035803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10.1177\/20552173211035803"],"URL":"https:\/\/doi.org\/10.1177\/20552173211035803","relation":{},"ISSN":["2055-2173","2055-2173"],"issn-type":[{"type":"print","value":"2055-2173"},{"type":"electronic","value":"2055-2173"}],"subject":[],"published":{"date-parts":[[2021,7]]},"article-number":"20552173211035803"}}